Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 26053

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Cancer
  • Therapeutic
  • Delivery
  • Addiction
  • Bacterial Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26053

License Grant
Licensor hereby grants to Swiss Licensee, and Licensee hereby accepts, an exclusive royalty-bearing license (with the right to sublicense with the consent of Licensor, which consent shall not be unreasonably withheld or delayed), to make, have made, use, import, sell and offer to sell the Methylphenidate Products in the Field in the Territory under the Licensor Technology.
License Property
ADHD shall mean Attention Deficit Hyperactivity Disorder.
d-MPH IR shall mean d-methylphenidate immediate release form.
d-MPH PR shall mean d-methylphenidate pulsed release form.

FOCALIN® and FOCALIN XR® are the long-acting drug formulation for attention deficit disorder, or ADD, and attention deficit hyperactivity disorder, or ADHD.

The Licensor has retained the exclusive commercial rights to FOCALIN® and FOCALIN XR® for oncology-related disorders, such as chronic fatigue associated with chemotherapy. The Licensor also granted  rights to all of its related intellectual property and patents, including formulations of the currently marketed RITALIN LA®.

U.S. Patent: 5,733,756 Process for Biocatalytic Resolution
U.S. Patent: 5,936,091 Process for Optical Resolution of Amide (Threo) intermediate
U.S. Patent: 5,837,284 Delivery of Multiple of Multiple doses of Methylphenidate
U.S. Patent: 5,908,850 Method of treating Attention Deficit Disorders with  D-Threo- Methylphenidate
U.S. Patent: 5,922,736 Chronic Bolus Administration OF D-Threo-Methylphenidate
U.S. Patent: 5,965,734 Process for Optical Resolution of Amide (Erythro) intermediates
U.S. Divisional Application (CELG-0085, the Divisional from CELG-0008); Serial No. 038470, filed March 11,1998.

Field of Use
Field shall mean administration of methylphenidate for the treatment of ADD and ADHD, and all other human disease indications other than disease indications in the field of oncology.

IPSCIO Record ID: 287024

License Grant
Licensor has the right to receive a royalty generated by KP415, KP484 or KP879, and any product candidates arising therefrom, including royalty payments on any license of KP415, KP484 or KP879, the sale of KP415, KP484 or KP879 to a third party, the commercialization of KP415, KP484 or KP879.
License Property
The products for the treatment of ADHD include KP415 and KP484, and the Companys preclinical product candidate for the treatment of SUD includes KP879.
Field of Use
KP415 is Licensee’s prodrug product candidate being developed for the treatment of ADHD. KP415 consists of serdexmethylphenidate (SDX), Licensee’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH. KP415 is designed to address unmet needs with the most prescribed methylphenidate ADHD treatments, including earlier onset of action and longer duration of therapy. In addition, the results from the Human Abuses Potential program for the SDX component of KP415 suggest that the prodrug may have lower abuse potential than relevant d-MPH comparators.

KP484 is Licensee’s co-lead clinical development candidate being developed for the treatment of ADHD in patients that respond best when a very long duration of therapy is required. Similar to KP415, KP484 consists of SDX, Licensee’s prodrug of d-MPH. Preclinical and clinical studies of KP484 have demonstrated that the prodrug may produce a longer duration release of d-MPH compared to the most prescribed methylphenidate products. KP484 has the potential to be the first new methylphenidate-based product being developed with the intent to address the specific needs of the adult ADHD population.
Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity and acting without regards to consequences, which are otherwise not appropriate for a person's age.

KP879 is an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder, or SUD.
A substance use disorder (SUD), also known as a drug use disorder, is a medical condition in which the use of one or more substances leads to a clinically significant impairment or distress.

IPSCIO Record ID: 266811

License Grant
Licensor grants a license, under the Adderall XR Intellectual Property and under any and all statutory and regulatory exclusivities issued by any Governmental Authority to import, Manufacture, have Manufactured and Market Licensee Product in the Territory on and after the License Effective Date. Notwithstanding the foregoing, Licensee shall have the limited right to Manufacture and/or import reasonable quantities of Licensee Product prior to the License Effective Date for the sole purpose of launching and selling such Product in the Territory under the foregoing license on and after the License Effective Date.

In the event a Third Party, without any cooperation or assistance from Licensee, markets a Generic Equivalent in the Territory prior to the License Effective Date, and Licensor elects, in its sole discretion, to market or have marketed a Generic Product to compete with such Third Party prior to the License Effective Date, then Licensor shall appoint Licensee as the exclusive, even as to Licensor, but except as to the Third Party Licensee.

License Property
Licensor is the owner of a New Drug Application, No. 21-303, which was approved by the Food and Drug Administration for the manufacture and sale of a pharmaceutical composition containing mixed amphetamine salts for the treatment of Attention Deficit Hyperactivity Disorder, all strengths of which Licensor sells under the trade name Adderall XR.

Adderall XR Intellectual Property shall mean U.S. Patent Nos. 6,322,819, 6,605,300, and 6,913,768 and any patent that issues as a result of a reexamination or reissue thereof; any patent that issues from, or any continuation, continuation-in-part or divisional application relating to, U.S. Patent Application Serial Nos. 09/176,542, 10/353,073, 10/758,417, 10/774,697, and 11/030,174; and any other present or future U S. patent owned or controlled by Licensor and its Affiliates which may be infringed by the making, using, selling or importing of the Generic Product.

Compound shall mean mixed amphetamine salts, as further defined in the NDA.

Field of Use
The field of  use is as a pulsed dose delivery system for amphetamine salts and mixtures.

Licensor has settled all pending litigation with Licensee in connection with Barr's Abbreviated New Drug Application ('ANDA') and its attempt to market generic versions of Licensor's ADDERALL XR (extended-release mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder ('ADHD').

IPSCIO Record ID: 5732

License Grant
We entered into an exclusive Licensing Agreement to develop a series of methylphenidate analogs or Ritalin-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression.
License Property
The licensed compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD.  The analogs are designed specifically to have a slow onset and increased half-life in the bloodstream, thus reducing a patient's required daily dosage and the potential for drug abuse.  We have the exclusive right to develop, use, market and sell products derived from the licensed compounds.

The Licensed compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the bloodstream, thus reducing a patient's required daily dosage and the potential for drug.

Field of Use
Field means all uses or potential uses of the Compounds, including all therapeutic, diagnostic, and prophylactic uses.

IPSCIO Record ID: 266736

License Grant
Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property
Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use
The Licensed Field means the use of rifaximin to treat any disease state claimed in whole or in part by a valid claim contained in the patent rights. It is the intent of the parties that the Licensed Field will not include any use of the Patent Rights or Licensed Technology for diagnostic purposes.

Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.